Triple

T9524839
Position Surface form Disambiguated ID Type / Status
Subject amantadine E229732 entity
Predicate hasBrandName P40804 FINISHED
Object Symmetrel
Symmetrel is a brand-name antiviral and antiparkinsonian medication whose active ingredient is amantadine.
 E804596 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Symmetrel | Statement: [amantadine, hasBrandName, Symmetrel]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Symmetrel
Context triple: [amantadine, hasBrandName, Symmetrel]
  • A. Acurenam
    Acurenam is a town located in the Centro Sur province of Equatorial Guinea.
  • B. Namenda
    Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
  • C. Donepezil
    Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.
  • D. Rinvoq
    Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
  • E. rivastigmine
    Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Symmetrel
Triple: [amantadine, hasBrandName, Symmetrel]
Generated description
Symmetrel is a brand-name antiviral and antiparkinsonian medication whose active ingredient is amantadine.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Symmetrel
Target entity description: Symmetrel is a brand-name antiviral and antiparkinsonian medication whose active ingredient is amantadine.
  • A. Acurenam
    Acurenam is a town located in the Centro Sur province of Equatorial Guinea.
  • B. Namenda
    Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
  • C. Donepezil
    Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.
  • D. Rinvoq
    Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
  • E. rivastigmine
    Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69ca847870a881909d8d751a7d29da39 completed March 30, 2026, 2:11 p.m.
NER Named-entity recognition batch_69cd9899f99481908d374528716027f8 completed April 1, 2026, 10:13 p.m.
NED1 Entity disambiguation (via context triple) batch_69d13a63fb98819095ef44ba26b6be03 completed April 4, 2026, 4:20 p.m.
NEDg Description generation batch_69d13b1a07cc8190a3e3f554f81b2ab2 completed April 4, 2026, 4:23 p.m.
NED2 Entity disambiguation (via description) batch_69d13f0eed008190b43e7c7f998188b7 completed April 4, 2026, 4:40 p.m.
Created at: March 30, 2026, 7:59 p.m.